# Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

> **NCT00772395** · PHASE4 · COMPLETED · sponsor: **Danderyd Hospital** · enrollment: 78 (actual)

## Conditions studied

- Bone Loss

## Interventions

- **DRUG:** Risedronate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00772395
- **Lead sponsor:** Danderyd Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2014-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772395, "Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00772395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*